{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignancies&page=21", "query": { "condition": "Malignancies", "page": 21 }, "page_size": 10 }, "pagination": { "page": 21, "page_size": 10, "total_count": 50316, "total_pages": 5032, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignancies&page=22&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignancies&page=20&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T01:36:40.633Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02465983", "title": "Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "CART-meso-19 T cells", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2015-05", "completion_date": "2017-11", "has_results": false, "last_update_posted_date": "2019-12-16", "last_synced_at": "2026-10-23T01:36:40.633Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02465983" }, { "nct_id": "NCT03521154", "title": "A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non Small Cell Lung Cancer (Stage III)" ], "interventions": [ { "name": "Osimertinib 80mg/40mg", "type": "DRUG" }, { "name": "Placebo Osimertinib 80mg/40mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 216, "start_date": "2018-07-19", "completion_date": "2027-10-29", "has_results": true, "last_update_posted_date": "2026-08-04", "last_synced_at": "2026-10-23T01:36:40.633Z", "location_count": 5, "location_summary": "Duarte, California • Atlanta, Georgia • Florham Park, New Jersey + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Florham Park", "state": "New Jersey" }, { "city": "Salt Lake City", "state": "Utah" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03521154" }, { "nct_id": "NCT03317405", "title": "Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Carcinoma In Situ", "Breast Ductal Carcinoma In Situ", "Breast Lobular Carcinoma In Situ", "Stage I Breast Cancer AJCC v7", "Stage IA Breast Cancer AJCC v7", "Stage IB Breast Cancer AJCC v7", "Stage II Breast Cancer AJCC v6 and v7", "Stage IIA Breast Cancer AJCC v6 and v7", "Stage IIB Breast Cancer AJCC v6 and v7", "Stage III Breast Cancer AJCC v7", "Stage IIIA Breast Cancer AJCC v7", "Stage IIIB Breast Cancer AJCC v7", "Stage IIIC Breast Cancer AJCC v7" ], "interventions": [ { "name": "Endoxifen Hydrochloride", "type": "DRUG" }, { "name": "Placebo Administration", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 32, "start_date": "2018-10-31", "completion_date": "2027-08-12", "has_results": true, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-10-23T01:36:40.633Z", "location_count": 3, "location_summary": "Los Angeles, California • Chicago, Illinois • New York, New York", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03317405" }, { "nct_id": "NCT02441686", "title": "Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Stem Cell Mobilization", "type": "PROCEDURE" }, { "name": "Autologous Stem Cell Transplant", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2015-12", "completion_date": "2025-10", "has_results": true, "last_update_posted_date": "2026-01-13", "last_synced_at": "2026-10-23T01:36:40.633Z", "location_count": 8, "location_summary": "Denver, Colorado • Brewer, Maine • Boston, Massachusetts + 3 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Brewer", "state": "Maine" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02441686" }, { "nct_id": "NCT02982941", "title": "Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neuroblastoma", "Rhabdomyosarcoma", "Osteosarcoma", "Ewing Sarcoma", "Wilms Tumor", "Desmoplastic Small Round Cell Tumor" ], "interventions": [ { "name": "Enoblituzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "35 Years", "sex": "ALL", "summary": "1 Year to 35 Years" }, "enrollment_count": 25, "start_date": "2016-12", "completion_date": "2019-05-22", "has_results": false, "last_update_posted_date": "2022-02-08", "last_synced_at": "2026-10-23T01:36:40.633Z", "location_count": 6, "location_summary": "Palo Alto, California • Bethesda, Maryland • Philadelphia, Pennsylvania + 3 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02982941" }, { "nct_id": "NCT04312841", "title": "Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "B-Cell Prolymphocytic Leukemia", "Chronic Lymphocytic Leukemia", "Peripheral T-Cell Lymphoma", "Primary Cutaneous T-Cell Non-Hodgkin Lymphoma", "Sezary Syndrome", "T-Cell Prolymphocytic Leukemia" ], "interventions": [ { "name": "Letermovir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2020-09-15", "completion_date": "2024-04-09", "has_results": true, "last_update_posted_date": "2025-02-28", "last_synced_at": "2026-10-23T01:36:40.633Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04312841" }, { "nct_id": "NCT00857805", "title": "Transarterial Chemoembolization Versus Proton Beam Radiotherapy for the Treatment of Hepatocellular Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Carcinoma, Hepatocellular" ], "interventions": [ { "name": "Transarterial Chemoembolization", "type": "PROCEDURE" }, { "name": "Proton Beam Radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "RADIATION" ], "sponsor": "Loma Linda University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 76, "start_date": "2009-01-07", "completion_date": "2021-07-07", "has_results": true, "last_update_posted_date": "2024-05-31", "last_synced_at": "2026-10-23T01:36:40.633Z", "location_count": 1, "location_summary": "Loma Linda, California", "locations": [ { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00857805" }, { "nct_id": "NCT02008994", "title": "Phase II Study Using Genomic & Proteomic Profiling to Influence Treatments for Patients With Metastatic Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Genomic and Proteomic Profiling", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Sanford Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2013-09", "completion_date": "2014-01", "has_results": false, "last_update_posted_date": "2015-03-24", "last_synced_at": "2026-10-23T01:36:40.633Z", "location_count": 1, "location_summary": "Sioux Falls, South Dakota", "locations": [ { "city": "Sioux Falls", "state": "South Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02008994" }, { "nct_id": "NCT03535766", "title": "An Analysis of Treatment Timelines for Lung Cancer Patients Across System Evolutions", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Lung Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "St Elizabeth Healthcare", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2100, "start_date": "2018-03-01", "completion_date": "2023-01-09", "has_results": false, "last_update_posted_date": "2024-07-12", "last_synced_at": "2026-10-23T01:36:40.633Z", "location_count": 1, "location_summary": "Edgewood, Kentucky", "locations": [ { "city": "Edgewood", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT03535766" }, { "nct_id": "NCT04262466", "title": "Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Select Advanced Solid Tumors" ], "interventions": [ { "name": "Brenetafusp", "type": "DRUG" }, { "name": "Brenetafusp and pembrolizumab", "type": "DRUG" }, { "name": "Brenetafusp and chemotherapy", "type": "DRUG" }, { "name": "Brenetafusp and monoclonal antibodies and chemotherapy", "type": "DRUG" }, { "name": "Brenetafusp and tebentafusp", "type": "DRUG" }, { "name": "Brenetafusp and bevacizumab", "type": "DRUG" }, { "name": "Brenetafusp and kinase inhibitors", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Immunocore Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 410, "start_date": "2020-02-25", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-03-06", "last_synced_at": "2026-10-23T01:36:40.633Z", "location_count": 22, "location_summary": "La Jolla, California • Los Angeles, California • Sacramento, California + 17 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04262466" } ] }